New Roles for Fusobacterium nucleatum in Cancer: Target the Bacteria, Host, or Both?
Anti-Bacterial Agents
/ pharmacology
Anti-Inflammatory Agents
/ pharmacology
Antineoplastic Agents
/ pharmacology
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Bacterial Proteins
/ antagonists & inhibitors
Carcinogenesis
/ genetics
Colorectal Neoplasms
/ drug therapy
DNA Damage
/ drug effects
Fusobacterium Infections
/ drug therapy
Fusobacterium nucleatum
/ drug effects
Host-Pathogen Interactions
/ drug effects
Humans
Mouth Mucosa
/ microbiology
Tumor Microenvironment
/ drug effects
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
11
08
2020
revised:
12
11
2020
accepted:
13
11
2020
pubmed:
15
12
2020
medline:
21
12
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Fusobacterium nucleatum is an oral bacterium associated with colorectal cancer (CRC) proliferation, chemoresistance, inflammation, metastasis, and now DNA damage. While controlling F. nucleatum through antibiotics could reduce cancer severity, this article proposes additional strategies to block Fusobacterium-host interactions, as well as treatment of activated host immune and oncogenic signaling pathways in CRC.
Identifiants
pubmed: 33309240
pii: S2405-8033(20)30307-1
doi: 10.1016/j.trecan.2020.11.006
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Anti-Inflammatory Agents
0
Antineoplastic Agents
0
Bacterial Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
185-187Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.